• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form NT 10-Q filed by Denali Capital Acquisition Corp.

    11/14/24 4:15:10 PM ET
    $DECA
    Blank Checks
    Finance
    Get the next $DECA alert in real time by email
    NT 10-Q 1 ea0221221-nt10q_denali.htm NOTIFICATION OF LATE FILING

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 12b-25

     

    NOTIFICATION OF LATE FILING

     

    (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN
      ☐ Form N-CSR
       
      For Period Ended: September 30, 2024
       
      ☐ Transition Report on Form 10-K
      ☐ Transition Report on Form 20-F
      ☐ Transition Report on Form 11-K
      ☐ Transition Report on Form 10-Q
       
      For the Transition Period Ended:

     

    Read Instruction (on back page) Before Preparing Form. Please Print or Type.
    Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

     

    If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

     

    PART I – REGISTRANT INFORMATION

     

    Denali Capital Acquisition Corp.
    Full Name of Registrant
     
    N/A
    Former Name if Applicable
     
    437 Madison Avenue, 27th Floor
    Address of Principal Executive Office (Street and Number)
     
    New York, New York 10022
    City, State and Zip Code

     

     

     

    PART II – RULES 12b-25(b) AND (c)

     

    If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

     

    (a)The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;

     

    ☒ (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and

     

    (c)The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

     

    PART III – NARRATIVE

     

    State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

     

    Denali Capital Acquisition Corp. (the “Registrant”) is unable, without unreasonable effort or expense, to file its Quarterly Report on Form 10-Q for the period ended September 30, 2024 (the “Quarterly Report”) within the prescribed filing date of November 14, 2024, due to a delay experienced by the Registrant in completing its financial statements and other disclosures in the Quarterly Report. As a result, the Registrant is still in the process of compiling required information to complete the Quarterly Report for the quarter ended September 30, 2024, to be incorporated in the Quarterly Report. The Registrant anticipates that it will file the Quarterly Report no later than the fifth calendar day following the prescribed filing date.

     

    PART IV – OTHER INFORMATION

     

    (1) Name and telephone number of person to contact in regard to this notification

     

    Lei Huang   646   978-5180
    (Name)   (Area Code)   (Telephone Number)

     

    (2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s). Yes ☒ No ☐

     

    (3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? Yes ☐ No ☒

     

    2

     

    Denali Capital Acquisition Corp.

    (Name of registrant as Specified in Charter)

     

    has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: November 14, 2024 By: /s/ Lei Huang
      Name: Lei Huang
      Title: Chief Executive Officer

     

    INSTRUCTION: The form may be signed by an executive officer of the registrant or by any other duly authorized representative. The name and title of the person signing the form shall be typed or printed beneath the signature. If the statement is signed on behalf of the registrant by an authorized representative (other than an executive officer), evidence of the representative’s authority to sign on behalf of the registrant shall be filed with the form.

     

    ATTENTION
    Intentional misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001).

     

     

    3

     

     

    Get the next $DECA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DECA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $DECA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Large owner Denali Capital Global Investments Llc

    4 - Denali Capital Acquisition Corp. (0001913577) (Issuer)

    9/16/24 10:05:57 AM ET
    $DECA
    Blank Checks
    Finance

    SEC Form 4 filed by Large owner Xu Jiandong

    4 - Denali Capital Acquisition Corp. (0001913577) (Issuer)

    9/16/24 10:01:42 AM ET
    $DECA
    Blank Checks
    Finance

    $DECA
    SEC Filings

    View All

    Denali Capital Acquisition Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - Denali Capital Acquisition Corp. (0001913577) (Filer)

    4/22/25 5:10:19 PM ET
    $DECA
    Blank Checks
    Finance

    Amendment: SEC Form S-4/A filed by Denali Capital Acquisition Corp.

    S-4/A - Denali Capital Acquisition Corp. (0001913577) (Filer)

    4/21/25 5:17:32 PM ET
    $DECA
    Blank Checks
    Finance

    Denali Capital Acquisition Corp. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits

    8-K - Denali Capital Acquisition Corp. (0001913577) (Filer)

    4/15/25 9:20:12 PM ET
    $DECA
    Blank Checks
    Finance

    $DECA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Denali Capital Acquisition Corp. Announces Extension of Deadline to Complete Business Combination

    NEW YORK, NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) -- Denali Capital Acquisition Corp. (NASDAQ:DECA) (the "Company") announced today that it has deposited into the Company's trust account (the "Trust Account") an aggregate of $874.78 to fund the one-month extension from June 11, 2025 to July 11, 2025. This deposit was funded via a convertible promissory note with a principal amount of up to $180,000 issued by the Company to Scilex Holding Company (NASDAQ:SCLX, "Scilex")), which bears no interest and is repayable on the earlier of the effective date of the consummation of the Company's initial business combination or the date of the liquidation of the Company. Upon the closing of a busines

    6/11/25 8:30:00 PM ET
    $DECA
    $SCLX
    Blank Checks
    Finance
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Denali Capital Acquisition Corp. Announces Extension of Deadline to Complete Business Combination

    NEW YORK, NEW YORK, May 09, 2025 (GLOBE NEWSWIRE) --  Denali Capital Acquisition Corp. (NASDAQ:DECA) (the "Company") announced today that it has deposited into the Company's trust account (the "Trust Account") an aggregate of $874.78 to fund the one-month extension from May 11, 2025 to June 11, 2025. This deposit was funded via a convertible promissory note with a principal amount of up to $180,000 issued by the Company to Scilex Holding Company (NASDAQ:SCLX, "Scilex")), which bears no interest and is repayable on the earlier of the effective date of the consummation of the Company's initial business combination or the date of the liquidation of the Company. Upon the closing of a business

    5/9/25 4:00:00 PM ET
    $DECA
    $SCLX
    Blank Checks
    Finance
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Denali Capital Acquisition Corp. Announces Shareholder Approval of Extension of Deadline to Complete Business Combination

    NEW YORK, NEW YORK, April 14, 2025 (GLOBE NEWSWIRE) -- Denali Capital Acquisition Corp. (NASDAQ:DECA) (the "Company") announced today that on April 11, 2025, the Company's shareholders voted in favor of approving amendments to the Company's amended and restated memorandum and articles of association (the "Articles") to extend the date by which the Company must consummate an initial business combination from April 11, 2025 to December 11, 2025 by electing to extend the date to consummate an initial business combination on a monthly basis for up to eight times by an additional one month each time (the "Extension"). The Company also announced today that on April 11, 2025, the Company deposit

    4/14/25 4:35:00 PM ET
    $DECA
    $SCLX
    Blank Checks
    Finance
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DECA
    Financials

    Live finance-specific insights

    View All

    Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, Announces Today the Filing of a Registration Statement on Form S-4 by Denali Capital Acquisition Corp. with the Securities and Exchange Commission Relating to the Previously Announced Proposed Business Combination Between Semnur and Denali

    As previously announced, Semnur Pharmaceuticals, Inc. ("Semnur"), a wholly owned subsidiary of Scilex Holding Company, and Denali Capital Acquisition Corp. (NASDAQ:DECA, the "SPAC")) entered into an agreement and plan of merger, dated as of August 30, 2024 (the "Merger Agreement"), related to the proposed business combination (the "Business Combination") of Denali and Semnur, which provides for a pre-transaction equity value of Semnur of $2.5 billion. The closing of the Business Combination is expected to occur by the first quarter of 2025. As previously disclosed, the Board of Directors of Scilex declared a stock dividend consisting of an aggregate of 5,000,000 shares of Series 1 Mandator

    11/6/24 12:24:36 PM ET
    $DECA
    $SCLX
    Blank Checks
    Finance
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Scilex Holding Company sets November 7, 2024 as the Record Date for a Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary

    Scilex notified NASDAQ on October 28, 2024 that it has set a record date of November 7, 2024 (the "Record Date") for the dividend of Scilex preferred stock to Scilex's stockholders and certain other securityholders of Scilex.Based on independent market research conducted by Syneos Health Consulting ("Syneos"), with the substantial intent in utilization for SP-102 (SEMDEXA™), the product candidate held by Semnur Pharmaceuticals, Inc. ("Semnur") is estimated to have peak sales potential projected to be $3.6 billion annually in the 5th year post launch of SP-102.Scilex previously announced that it anticipates the filing of a Registration Statement on Form S-4 (the "Registration Statement") with

    10/28/24 6:00:00 AM ET
    $DECA
    $SCLX
    Blank Checks
    Finance
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, Provides Timing to File in October 2024 a Registration Statement on Form S-4 with the SEC relating to the Previously Announced Proposed Business Combination Between Semnur and Denali with a Pre-Transaction Equity Value of $2.5 Billion

    Semnur is currently in discussions regarding strategic regional and/or worldwide collaborations and potential outright acquisition of SP-102. Any such transactions may have the potential to provide value in excess of $2.5 billion after the proposed business combination (the "Business Combination") with Denali Capital Acquisition Corp. (NASDAQ:DECA, the "SPAC"))).Based on an independent market research conducted by Syneos Health Consulting ("Syneos"), with the substantial intent in utilization for SP-102 (SEMDEXA™) with peak sales potential projected to reach $3.6 billion annually in the 5th year post launch of SP-102.Semnur Pharmaceuticals, Inc. ("Semnur"), a wholly owned subsidiary of Scile

    10/16/24 4:00:00 AM ET
    $DECA
    $SCLX
    Blank Checks
    Finance
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DECA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Denali Capital Acquisition Corp.

    SC 13G/A - Denali Capital Acquisition Corp. (0001913577) (Subject)

    12/6/24 4:17:05 PM ET
    $DECA
    Blank Checks
    Finance

    Amendment: SEC Form SC 13G/A filed by Denali Capital Acquisition Corp.

    SC 13G/A - Denali Capital Acquisition Corp. (0001913577) (Subject)

    11/14/24 5:49:50 PM ET
    $DECA
    Blank Checks
    Finance

    Amendment: SEC Form SC 13G/A filed by Denali Capital Acquisition Corp.

    SC 13G/A - Denali Capital Acquisition Corp. (0001913577) (Subject)

    11/14/24 2:35:09 PM ET
    $DECA
    Blank Checks
    Finance